Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Atopic Dermatitis
March 24, 2020 08:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, March 24, 2020 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a private Vancouver based start-up biopharmaceutical company focused on skin health and healthy...
New Eczema Report Depicts Enormous Burdens and Huge Unmet Medical Needs
March 18, 2020 11:00 ET
|
Asthma and Allergy Foundation of America
Washington, D.C., March 18, 2020 (GLOBE NEWSWIRE) -- Today, five organizations jointly release the “More Than Skin Deep” Voice of the Patient report summarizing outcomes from a September 2019...
ASLAN Pharmaceuticals Reports Positive Preliminary Data From Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis
December 02, 2019 02:07 ET
|
ASLAN PHARMACEUTICALS LIMITED
- ASLAN004 demonstrates early signs of efficacy in the low dose cohort of multiple ascending dose study - 3 patients completed 1 month of dosing and achieved average reduction in EASI score of 71%....
ASLAN Pharmaceuticals Enrolls First Patient in Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis
October 22, 2019 02:45 ET
|
ASLAN PHARMACEUTICALS LIMITED
- Multiple ascending dose study will assess the safety and efficacy of ASLAN004 in patients with moderate to severe atopic dermatitis - ASLAN004 has previously demonstrated a favourable tolerability...
Individuals & Families Affected by Eczema Unite to Inform Drug Development
August 01, 2019 13:00 ET
|
Asthma and Allergy Foundation of America
Washington, D.C., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Today, five organizations launch a collaborative effort to inform treatment research and development for atopic dermatitis, the most common form...
ASLAN Pharmaceuticals Completes Phase 1 Study for ASLAN004 Targeting Atopic Dermatitis
June 04, 2019 08:00 ET
|
ASLAN Pharmaceuticals Limited
- Final results from single ascending dose study confirm ASLAN004’s favourable tolerability profile, complete inhibition of downstream mediators and potential for monthly dosing SINGAPORE, June ...
ASLAN Pharmaceuticals Acquires Full Global Commercial Rights for ASLAN004 From CSL
May 31, 2019 03:15 ET
|
ASLAN Pharmaceuticals Limited
- Amending their previous agreement, CSL grants ASLAN full global rights to develop, manufacture and commercialise ASLAN004 SINGAPORE, May 31, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals...
Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology
May 07, 2019 16:15 ET
|
Novan, Inc.
MORRISVILLE, N.C., May 07, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that recent data from the Company’s Phase 1b trial with SB414 cream for the...
ASLAN Pharmaceuticals Completes First Part of Single Ascending Dose Study for ASLAN004 Targeting Atopic Dermatitis
March 29, 2019 05:50 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, March 29, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company developing novel therapeutics for global markets, today...
MatriSys Bioscience announces successful FDA Pre-IND review and Phase 2 plans for MSB-01, a revolutionary human-microbiome based treatment for Atopic Dermatitis
March 20, 2019 19:55 ET
|
MatriSys Bioscience
SAN DIEGO, March 20, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a clinical stage biotechnology company developing rationally designed microbiome therapeutics to treat the top five skin...